Leadership

Frank G. Haluska, MD, PhD | President and Chief Executive Officer

Biography

Dr. Haluska has served as CEO of Anchiano since October 2016. He most recently served as Chief Medical Officer and Senior Vice President of Clinical R&D at ARIAD Pharmaceuticals, Inc., where he held overall responsibility for clinical development strategy. At ARIAD he led the clinical development and approval of ponatinib (marketed as Iclusig) in the US, EU and other territories, as well as the development of brigatinib (marketed as Alunbrig) approved in the US by the FDA.

Dr. Haluska graduated from Harvard College and the University of Pennsylvania School of Medicine, undertook medical training at Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI), and a fellowship at the Massachusetts Institute of Technology Center for Cancer Research. He became assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at the MGH Cancer Center and the DFCI through the Dana-Farber Harvard Cancer Center. Subsequently he was deputy director of the Tufts New England Medical Center Cancer Center. 

Steve DiPalma | Chief Financial Officer

 

 

 

 

Biography

Mr. DiPalma brings more than 30 years of experience in life sciences and healthcare and has served as a Senior Financial Advisor to Anchiano by agreement with Danforth since 2018. Mr. DiPalma has served as the Chief Financial Officer and finance lead for eight public companies prior to and since joining Danforth, and has served as Chief Financial Officer, Chief Operating Officer, Chief Executive Officer or Director of eight privately-held companies. In these roles, Mr. DiPalma has managed finance, accounting, and a variety of corporate functions successfully. He has extensive experience in international fundraising and corporate structuring. Mr. DiPalma received his M.B.A. from Babson College and his B.S. from the University of Massachusetts-Lowell.

David Kerstein, MD | Chief Medical Officer and Senior Vice President

 

 

 

 

Biography

Dr. David Kerstein has served as Anchiano’s Chief Medical Officer since November 2018. Prior to joining Anchiano, Dr. Kerstein served as Senior Medical Director of Oncology Clinical Research at Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company. At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for the ALK inhibitor, brigatinib. Prior to that, Dr. Kerstein was Medical Director and then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program, and led the initial New Drug Application and Marketing Authorization Application submissions and approvals for brigatinib. Previously, at Boston Biomedical, Dainippon Sumitomo Pharma Global Oncology, he was Director of Clinical Development and Regulatory Affairs. Dr. Kerstein received his M.D. from Tufts University School of Medicine and his B.S. in biology, summa cum laude, from Tufts University.

Ron Knickerbocker, PhD | Senior Vice President of Clinical Development and Data Sciences 

 

 

 

 

Biography

Dr. Knickerbocker is Senior Vice President, Clinical Development at Anchiano (formerly BioCanCell) since March 2018. Prior to this Dr. Knickerbocker led the Biomedical Data Sciences and Information group at ARIAD Pharmaceuticals from 2012 until its acquisition by Takeda in 2017. At ARIAD, he led statistics and data management functions through multiple successful oncology submissions. Prior to this, Dr. Knickerbocker served as a Vice President at Genzyme corporation from 2004 to 2012, where his positions included leading the biostatistics, data management, and medical writing functions for the transplant/oncology business and global head of biostatistics and statistical programming. From 1999 to 2004 Dr. Knickerbocker was the statistical site head for Pfizer Inc. in Ann Arbor, MI. From 1993 to 1999, he held positions at Eli Lilly and Company, leading projects in women’s health and oncology. He has a B.S. degree in Applied Mathematics and his M.S. and Ph.D. degrees in Statistics from Texas A&M University.

 

Sean Daly | Vice President of Clinical Operations 

 

 

 

 

Biography

Mr. Daly has served as Anchiano’s Vice President of Clinical Operations since March 2018 and brings more than a decade of experience and an ample network of synergetic relationships to his role. Mr. Daly joined Anchiano from ARIAD Pharmaceuticals, where he most recently served as the Vice President of Clinical Operations. Sean led the clinical operations group at ARIAD for five years, building upon various operational roles held at ARIAD since 2004. In addition to his experience at ARIAD, he has held positions with Wyeth Research (formerly Genetics Institute) and Agouron Pharmaceuticals. Sean is a graduate of the University of California at San Diego where he received his B.S. in Biochemistry and Cell Biology.

 

Salar Roshan | Head of Business Development

Biography

Mr. Roshan has served as our Head of Business Development since May 2019. Mr. Roshan leads the development of strategic partnerships and spearheaded the licensing transaction surrounding our pan-RAS and PDE10/β-catenin programs. Mr. Roshan joined Anchiano Therapeutics from Curis, Inc., an anti-cancer biotechnology company, where he served as Head of Corporate Development and was responsible for overseeing all aspects of the company’s corporate and business development strategy. Prior to that, he led the partial spin-off of the R&D division of Baxter Biosciences into Baxalta. While at Baxalta, he was also responsible for several product launches and oversaw valuation and long range planning for the hemophilia portfolio, which grossed roughly $4 billion in annual sales prior to Baxalta’s merger with Shire PLC. Mr. Roshan has also held roles of increasing responsibility at Ironwood Pharmaceuticals, Takeda US, Millennium Pharmaceuticals, and Genzyme. Mr. Roshan received his M.Sc. in finance and his M.B.A. from Kelley School of Business at Indiana University, and his B.Sc. in biotechnology from Northeastern University.